share_log

OrbusNeich Medical Group Holdings Limited Just Recorded A 21% EPS Beat: Here's What Analysts Are Forecasting Next

OrbusNeich Medical Group Holdings Limited Just Recorded A 21% EPS Beat: Here's What Analysts Are Forecasting Next

OrbusNeich Medical Group Holdings Limited剛剛錄得21%的每股收益增長:以下是分析師的預測下一步
Simply Wall St ·  03/09 19:29

Last week, you might have seen that OrbusNeich Medical Group Holdings Limited (HKG:6929) released its annual result to the market. The early response was not positive, with shares down 9.5% to HK$3.98 in the past week. It looks like a credible result overall - although revenues of US$154m were what the analysts expected, OrbusNeich Medical Group Holdings surprised by delivering a (statutory) profit of US$0.055 per share, an impressive 21% above what was forecast. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

上週,你可能已經看到奧布斯尼奇醫療集團控股有限公司(HKG: 6929)向市場發佈了其年度業績。早期的反應並不樂觀,過去一週股價下跌9.5%,至3.98港元。總體而言,這似乎是一個可信的業績——儘管分析師預期的收入爲1.54億美元,但OrbusNeich Medical Group Holdings出人意料地實現了每股0.055美元的(法定)利潤,比預期高出21%。分析師通常會在每份收益報告中更新他們的預測,我們可以從他們的估計中判斷他們對公司的看法是否發生了變化,或者是否有任何新的問題需要注意。因此,我們收集了最新的業績後預測,以了解估計對明年的預測。

earnings-and-revenue-growth
SEHK:6929 Earnings and Revenue Growth March 10th 2024
SEHK: 6929 2024 年 3 月 10 日的收益和收入增長

Following the latest results, OrbusNeich Medical Group Holdings' three analysts are now forecasting revenues of US$177.7m in 2024. This would be a solid 15% improvement in revenue compared to the last 12 months. Statutory per share are forecast to be US$0.055, approximately in line with the last 12 months. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$176.4m and earnings per share (EPS) of US$0.053 in 2024. So the consensus seems to have become somewhat more optimistic on OrbusNeich Medical Group Holdings' earnings potential following these results.

根據最新業績,OrbusNeich Medical Group Holdings的三位分析師現在預測2024年的收入爲1.777億美元。與過去12個月相比,這將使收入穩步增長15%。預計法定每股收益爲0.055美元,與過去12個月大致持平。然而,在最新業績公佈之前,分析師曾預計2024年的收入爲1.764億美元,每股收益(EPS)爲0.053美元。因此,在這些業績公佈後,人們對OrbusNeich Medical Group Holdings的盈利潛力的共識似乎變得更加樂觀了。

The average the analysts price target fell 18% to HK$6.96, suggesting thatthe analysts have other concerns, and the improved earnings per share outlook was not enough to allay them. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values OrbusNeich Medical Group Holdings at HK$8.01 per share, while the most bearish prices it at HK$5.81. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await OrbusNeich Medical Group Holdings shareholders.

分析師的平均目標股價下跌了18%,至6.96港元,這表明分析師還有其他擔憂,每股收益前景的改善不足以緩解這些擔憂。但是,固定單一價格目標可能是不明智的,因爲共識目標實際上是分析師目標股價的平均值。因此,一些投資者喜歡查看估計範圍,看看對公司的估值是否有任何分歧。目前,最看漲的分析師對OrbusNeich Medical Group Holdings的估值爲每股8.01港元,而最看跌的分析師估值爲5.81港元。分析師對該業務的看法肯定各不相同,但我們認爲,估計的分歧還不夠廣泛,不足以表明奧布斯內希醫療集團控股股東可能會有極端的結果。

Of course, another way to look at these forecasts is to place them into context against the industry itself. The period to the end of 2024 brings more of the same, according to the analysts, with revenue forecast to display 15% growth on an annualised basis. That is in line with its 17% annual growth over the past three years. Compare this with the broader industry (in aggregate), which analyst estimates suggest will see revenues grow 24% annually. So although OrbusNeich Medical Group Holdings is expected to maintain its revenue growth rate, it's forecast to grow slower than the wider industry.

當然,看待這些預測的另一種方法是將它們與行業本身聯繫起來。分析師表示,截至2024年底將帶來更多相同的情況,收入按年計算預計將增長15%。這與其在過去三年中17%的年增長率一致。相比之下,整個行業(總計),分析師估計,該行業的收入每年將增長24%。因此,儘管預計OrbusNeich Medical Group Holdings將保持其收入增長率,但預計其增長速度將低於整個行業。

The Bottom Line

底線

The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around OrbusNeich Medical Group Holdings' earnings potential next year. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that OrbusNeich Medical Group Holdings' revenue is expected to perform worse than the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of OrbusNeich Medical Group Holdings' future valuation.

對我們來說,最大的收穫是共識的每股收益上調,這表明圍繞OrbusNeich Medical Group Holdings明年盈利潛力的情緒明顯改善。幸運的是,分析師還重申了他們的收入預期,表明收入符合預期。儘管我們的數據確實表明,預計OrbusNeich Medical Group Holdings的收入表現將低於整個行業。共識目標股價大幅下降,分析師似乎沒有對最新業績感到放心,這導致對奧布斯內希醫療集團控股公司未來估值的估計降低。

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple OrbusNeich Medical Group Holdings analysts - going out to 2026, and you can see them free on our platform here.

考慮到這一點,我們仍然認爲該業務的長期發展軌跡對於投資者來說更爲重要。根據多位OrbusNeich Medical Group Holdings分析師的估計,到2026年,你可以在我們的平台上免費查看。

You can also see our analysis of OrbusNeich Medical Group Holdings' Board and CEO remuneration and experience, and whether company insiders have been buying stock.

您還可以看到我們對OrbusNeich Medical Group Holdings董事會和首席執行官薪酬和經驗的分析,以及公司內部人士是否一直在購買股票。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論